A Phase 3 clinical trial designed to evaluate if an investigational vaccine can prevent symptomatic coronavirus disease 2019 (COVID-19) in adults is under way. The vaccine, mRNA-1273, was co-developed by the Cambridge, Massachusetts-based biotechnology company Moderna, Inc., and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The trial, which will be conducted at U.S. clinical research sites, is expected to enroll approximately 30,000 adult volunteers who do not have COVID-19.


Pfizer and BioNTech have received FDA's Fast Track designation for two of the companies' four investigational vaccine candidates from their BNT162 mRNA-based vaccine program (BNT162b1 and BNT162b2) being developed to help protect against SARS-CoV-2. This designation was granted based on preliminary data from Phase 1/2 studies that are ongoing in the United States and Germany, as well as animal immunogenicity studies. The companies released early data from the ongoing U.S....

You do not currently have access to this content.